Mosaic ImmunoEngineering Inc.
CPMV- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000836564
No open-market purchases or sales by Mosaic ImmunoEngineering Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q3 2026; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 11:41 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Operating expenses | $616.1K | $879.7K | $1.40M | $2.63M | $3.50M |
| Research and development | $64.0K | $183.9K | $435.4K | $1.05M | $1.46M |
| Selling, general and administrative | $552.1K | $695.8K | $964.3K | $1.58M | $2.05M |
| Operating income | -$616.1K | -$879.7K | -$1.40M | -$2.63M | – |
| Interest expense | $10.0K | $6.95K | – | – | – |
| Income tax | $2.40K | $2.40K | $2.40K | $2.40K | $2.40K |
| Net income | -$687.8K | -$922.0K | -$1.01M | -$2.38M | -$3.68M |
| EPS, basic | $-0.10 | $-0.13 | $-0.14 | $-0.33 | $-0.55 |
| EPS, diluted | $-0.10 | $-0.13 | $-0.14 | $-0.33 | $-0.55 |
| Weighted shares, basic | 7.24M | 7.24M | 7.24M | 7.24M | – |
| Weighted shares, diluted | – | 7.24M | 7.24M | 7.24M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Cash and equivalents | $3.62K | $115.0K | $156.2K | $220.6K | $226.1K |
| Total current assets | $19.9K | $141.6K | $179.5K | $261.3K | $269.5K |
| Total assets | $19.9K | $141.6K | $179.5K | $261.3K | $269.5K |
| Accounts payable | $132.8K | $134.9K | $118.5K | $133.5K | $113.5K |
| Total current liabilities | $6.03M | $5.54M | $4.73M | $3.92M | $2.33M |
| Total liabilities | $7.50M | $6.93M | $6.05M | $5.15M | $3.07M |
| Shareholders' equity | -$7.48M | -$6.79M | -$5.87M | -$4.88M | -$2.80M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Operating cash flow | -$111.4K | -$241.2K | -$497.5K | -$690.1K | -$679.2K |
| Stock-based compensation | $0 | $4.87K | $21.9K | $295.1K | $1.31M |
| Investing cash flow | – | $0 | $433.0K | $343.0K | $27.6K |
| Financing cash flow | $0 | $200.0K | $0 | $341.6K | $525.0K |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 14, 2026 | 7.24M | 0.0% | SEC |
| May 20, 2026 | 7.24M | 0.0% | SEC |
| Apr 15, 2026 | 7.24M | 0.0% | SEC |
| Nov 19, 2025 | 7.24M | 0.0% | SEC |
| Aug 18, 2025 | 7.24M | 0.0% | SEC |
| May 20, 2025 | 7.24M | 0.0% | SEC |
| Apr 11, 2025 | 7.24M | 0.0% | SEC |
| Nov 14, 2024 | 7.24M | 0.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.